Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children

NCT00696423 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00696423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00696423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 7, 2008
Completion date
July 26, 2008
Enrollment
467 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, tetanus